URGENT PANDEMIC INFORMATION

In light of the pandemic situation events until September 2021 are cancelled. We will inform customers directly when the events are rescheduled.    
COVID CANCELLED: Project Management in Human Resources,   Boston MA, Jan 6-8, 2021
COVID CANCELLED: InterDrone, The International Drone Conference,   Cambridge MA, Jan 11-13, 2021
COVID CANCELLED: Supplier Management for Medical Device Manufacturers,   Cambridge MA, Feb 2-4, 2021
COVID CANCELLED: US Immigration Compliance Strategies,   Boston MA, Feb 15-18, 2021
COVID CANCELLED: Project Management Training,   Boston MA, Mar 3-5, 2021
COVID CANCELLED: Internal Audit, Fraud Risk Assessment Workshop,   Boston MA, Mar 22-25, 2021
COVID CANCELLED: Agile / Scrum Training,   Boston MA, Apr 12-14, 2021
COVID CANCELLED: Validation, Verification and Transfer of Analytical Methods,   Boston MA, Apr 19-21, 2021
COVID CANCELLED: Computer System Validation - Reduce Costs and Avoid 483s,   Boston MA, May 10-12, 2021
COVID CANCELLED: SharePoint Technology Conference,   Boston MA, May 26-28, 2021
COVID CANCELLED: Employment Laws Certificate Program,   Boston MA, Jun 7-9, 2021
Following events are tentatively planned but may be rescheduled, based on CDC guidelines or attendee registration interest .    
TENTATIVE: 21 CFR Part 11 Compliance,   Boston MA, Sep 22-24, 2021
TENTATIVE: Quality Control Laboratory Compliance,   Boston MA, Oct 6-8, 2021
TENTATIVE: Analytical Instrument Qualification and System Validation,   Boston MA, Nov 15-17, 2021
TENTATIVE: FDA's New Import Program for 2021,   Boston MA, Dec 7-9, 2021

Boston Professional Events List


13th Annual World Multispecifics Summit


Date
Sep 20, 2022 - 08:30 AM - Sep 22, 05:00 PM
Organizer
Hanson Wade
Venue
DoubleTree by Hilton Hotel Boston North Shore
Location
50 Ferncroft Road,

Danvers,
MA,
US,
ZIP: 01923
Phone: +1 617 455 4188

Ticket Price: USD 2599.00 - USD 5546.00


The Newly Re-Branded 13th World Multispecifics Summit is the Only End-to-End Meeting Committed Solely to Advancing the Development of Bi- & Multi-Specific Therapeutics

With more clinical candidates and commercial success than ever within this rapidly developing space, multi-specifics is evidently the fourth wave of drug discovery. With this, there has never been a hotter time to double down and deliver the holy grail of precision oncology as the true power of bispecifics is recognized.

The 13th Annual World Multispecific Summit will deliver a greater scope and penetration of innovative technical content than any other meeting. This year’s re-imagined agenda will cover unique target discovery, mechanistic diversity and translational science as well as novel formats, product design and manufacturability challenges faced in the bispecific field.

Whatever your role or interest, you will leave the meeting with concrete methods to employ in your strategy and pipeline to convert the promise of bi- and multi-specific therapeutics into a reality for patients.

With 2 tracks of unrivaled content, join with your team to catapult this community into the next generation of translational success, clinical progress, advanced mechanistic diversity, reduced toxicity and higher target affinity. Utilize the pre-conference focus day dedicated to Novel Formats and Immune Cell Modulators of multispecifics to further drive your clinical and antibody engineering strategies forward.

Tickets    https://go.evvnt.com/1160671-2?pid=1052
Brochure https://go.evvnt.com/1160671-3?pid=1052

Prices:
Conference + Focus Day - Industry Pricing USD 4646.00
Conference Only - Industry Pricing USD 2999.00
Conference + Focus Day - Academic & Non-Profit Pricing USD 3946.00
Conference Only - Academic & Non-Profit Pricing USD 2599.00
Conference + Focus Day - Service Provider Pricing USD 5546.00
Conference Only - Service Provider Pricing USD 3599.00

Category: Conferences | Science, Health & Medicine | Pharmaceuticals | Drug Development


Speaker Details


Alex Martinko, Co-Founder & Senior Director - Protein Science, Soteria Biotherapeutics, Alexander Haas, Head Biologics Core Technologies, Roche, Aman Singh, Associate Director, Cell Therapy Clinical Pharmacology, Modeling & Bioinformatics, Takeda, Ankita Srivastava, Vice President - Protein Sciences & Rational Design, Ichnos Sciences, Anthony Stein, Medical Doctor, City of Hope, Azra Mujic-Delic, Principal Scientist - Functional Characterization & Bioassays, Genmab, Brandon Leonard, Principal Scientific Researcher - Antibody Engineering, Genentech, Camille Grandclement, Senior Scientist, Ichnos Sciences, Chava Kimchi-Sarfat,y Deputy Associate Director - Research Office of Tissue & Advanced Therapies, CBER, FDA, Christopher Mehlin, Chief Scientific Officer & Co-founder, Link Immunotherapeutics, Daniel Pereira, Chief Scientific Officer, Invenra, David Poon, Vice President – Business Development & Alliance Management, Zymeworks, Diego Ellerman, Principal Scientific Researcher, Genentech, Erin Meermeier, Research Associate Scientist - Division of Hematology and Oncology, Mayo Clinic, Eugene Zhukovsky, Chief Scientific Officer, Ichnos Sciences, Ezio Bonvini, Chief Scientific Officer, Macrogenics, Harald Kolmar, Department Head Applied Biochemistry Technical, University of Darmstadt, Jeffrey Way, Lecturer - Department of Systems Biology, Harvard Medical School, Jonah Rainey, Vice President of Antibody Engineering and Protein Science, AlivaMab Discovery Services, Jonathan Davis, Vice President - Innovation and Strategy, Invenra, Julia Frei, Principal Scientist, Ichnos Sciences, Kalyan Pande, Associate Principal Scientist – Protein Engineering & Modalities, Merck, Liqin Liu Senior, Director of T Cell Engagers, IGM Biosciences, Martin Siegemund, Senior Scientist, Pieris Pharmaceuticals, Nimish Gera, Vice President - Biologics Research, Mythic Therapeutics, Peter Ellmark, Chief Scientific Officer, Alligator Bioscience, Pranjali Dalvi, Senior Scientist, Amgen, Prathap Shastri, Scientific Director, DMPK, Preclinical Sciences and Translational Safety, Johnson & Johnson, Rakesh Dixit, President and Head of R&D, Co-Founder, Regio Biosciences, Alexander Schinagl, PhD Chief Technology Officer, OncoOne, Shailee Patel, Researcher Beacon, Targeted Therapeutics, Shaun Lippow, Senior Director - Protein Engineering, Atreca, Suzanne Schubbert, Associate Director - Discovery Biology & Pharmacology, Xencor, Vera Sellers, Associate Director - Molecule Group, Protein & Cell Sciences Discovery & Development Technologies, EMD Serono, Wadim Matochko, Scientist Antibody Discovery, Amgen, Wei Yan, President & Chief Executive Officer, Sound Biologics, Werner Meier, Chief Scientific Officer, Revitope Oncology, Yanchen Zhou, Scientist, Amgen, Musheng Bao, Senior Director, Discovery Oncology, Harbour Biomed, Christel Iffland, PhD. VP, Antibody Technology, OmniAb, Inc.

Event Categories
Keywords: cytokin




Comments








Events Calendar

SunMonTueWedThuFriSat
28 29 30 31 1 2 3
4 5 6 7 8 9 10
11 12 13 14 15 16 17
18 19 20 21 22 23 24
25 26 27 28 29 30 1

Newsletters

VIP Life Time Subscription to our Newsletters!
$399.99
$299.99